Tr1X, pronounced "Trix", develops cell therapies to treat autoimmune and inflammatory diseases. Tr1X's therapies are based on regulatory T cell-based therapeutics that mimic the function of Type 1 regulatory T (Tr1) cells. Tr1X's cells work similarly to natural Tr1 cells by: (1) Homing to inflammation sites (2) Suppressing unwanted activity (3) Increasing the production of antigen-specific Tr1 cells (4) Resetting the immune system and restoring balance. Tr1X's technology is designed to convert donor-derived T cells into Treg-like cells. Treg-like cells have a similar function and profile to natural Tr1 cells.

<p>Tr1X, pronounced &quot;Trix&quot;, develops cell therapies to treat autoimmune and inflammatory diseases. Tr1X&#39;s therapies are based on regulatory T cell-based therapeutics that mimic the function of Type 1 regulatory T (Tr1) cells. Tr1X&#39;s cells work similarly to natural Tr1 cells by: (1) Homing to inflammation sites (2) Suppressing unwanted activity (3) Increasing the production of antigen-specific Tr1 cells (4) Resetting the immune system and restoring balance.</p>
<p>Tr1X&#39;s technology is designed to convert donor-derived T cells into Treg-like cells. Treg-like cells have a similar function and profile to natural Tr1 cells.</p>


Tr1X

Founded: 2018
Location: San Diego, CA
Employee range: 1-50
Clinical stage: Clin1
Therapy area: GvHD
Drug types: IMM
Lead product: TRX103
Funding: 10-100M

Tr1X

Drug notes:

About:

Jobs: